מכפיל EV/EBITDA: Soleno (SLNO)

DCCR approval will grant Soleno Therapeutics (SLNO) absolute pricing power due to highly inelastic demand. The company's EV/EBITDA ratio on the financial timeline confirms this trend, where the 28.06 mark serves as the current metric. A patent monopoly within the orphan disease niche guarantees high margins, while business success depends on clinical outcomes rather than market cycles.

Soleno Therapeutics (SLNO) focuses its highly specialized staff on the commercialization of a drug for the treatment of rare metabolic disorders. By analyzing the EV/EBITDA debt and operating leverage metric, an investor compares the total enterprise value with its earnings before depreciation and interest, which allows for an assessment of real market demand for the asset and the risk of overpayment during periods of rate volatility.